

Hannah Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8154127/publications.pdf>

Version: 2024-02-01

43
papers

2,375
citations

331670
21
h-index

302126
39
g-index

43
all docs

43
docs citations

43
times ranked

3027
citing authors

#	ARTICLE	IF	CITATIONS
1	Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. <i>Lancet Haematology</i> , 2016, 3, e426-e436.	4.6	322
2	14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Autoimmunity Reviews</i> , 2014, 13, 685-696.	5.8	290
3	Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2828-2839.	3.8	211
4	Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study. <i>Lancet Neurology</i> , 2018, 17, 539-547.	10.2	192
5	Patient self-testing is a reliable and acceptable alternative to laboratory INR monitoring. <i>British Journal of Haematology</i> , 2005, 128, 242-247.	2.5	101
6	Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type. <i>Neurology</i> , 2016, 86, 360-366.	1.1	99
7	Hydroxychloroquine to Improve Pregnancy Outcome in Women with Antiphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 562-571.	2.7	89
8	The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. <i>Blood Reviews</i> , 2020, 39, 100610.	5.7	85
9	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2126-2137.	3.8	84
10	Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. <i>Thrombosis and Haemostasis</i> , 2015, 113, 13-19.	3.4	81
11	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020, 29, 1571-1593.	1.6	80
12	Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. <i>Thrombosis and Haemostasis</i> , 2016, 116, 651-658.	3.4	79
13	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 464-468.	3.4	79
14	Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1569-1575.	3.8	76
15	The Clinical Relevance of Microbleeds in Stroke study (CROMIS-2): rationale, design, and methods. <i>International Journal of Stroke</i> , 2015, 10, 155-161.	5.9	51
16	Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: multicentre cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 320-325.	1.9	47
17	Small Vessel Disease and Ischemic Stroke Risk During Anticoagulation for Atrial Fibrillation After Cerebral Ischemia. <i>Stroke</i> , 2021, 52, 91-99.	2.0	40
18	Cognitive Impairment Before Intracerebral Hemorrhage Is Associated With Cerebral Amyloid Angiopathy. <i>Stroke</i> , 2018, 49, 40-45.	2.0	39

#	ARTICLE	IF	CITATIONS
19	Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management. Thrombosis Research, 2021, 198, 213-221.	1.7	39
20	Clinical and laboratory practice for lupus anticoagulant testing: An International Society of Thrombosis and Haemostasis Scientific and Standardization Committee survey. Journal of Thrombosis and Haemostasis, 2019, 17, 1715-1732.	3.8	32
21	Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome. Thrombosis Research, 2015, 135, 1191-1197.	1.7	31
22	Association of enlarged perivascular spaces and anticoagulant-related intracranial hemorrhage. Neurology, 2020, 95, e2192-e2199.	1.1	24
23	In utero exposure to Azathioprine in autoimmune disease. Where do we stand?. Autoimmunity Reviews, 2020, 19, 102525.	5.8	22
24	COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION). Lupus, 2021, 30, 2276-2285.	1.6	21
25	Monitoring of anticoagulation in thrombotic antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2021, 19, 892-908.	3.8	20
26	Under crossfire: thromboembolic risk in systemic lupus erythematosus. Rheumatology, 2019, 58, 940-952.	1.9	19
27	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report. , 2017, , 317-338.		19
28	How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome. Blood, 2021, 137, 299-309.	1.4	15
29	Cognitive dysfunction and associated neuroimaging biomarkers in antiphospholipid syndrome: a systematic review. Rheumatology, 2021, , .	1.9	13
30	Cerebral Small Vessel Disease and Functional Outcome Prediction After Intracerebral Hemorrhage. Neurology, 2021, 96, e1954-e1965.	1.1	10
31	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. Journal of Thrombosis and Haemostasis, 2019, 17, 2069-2080.	3.8	9
32	Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. Current Rheumatology Reports, 2021, 23, 45.	4.7	9
33	The prevalence of incidental uterine venous plexus thrombosis in women attending a gynecology clinic. Journal of Thrombosis and Haemostasis, 2020, 18, 2557-2565.	3.8	8
34	The assessment of patients with the antiphospholipid antibody syndrome: where are we now?. Rheumatology, 2020, 59, 1489-1494.	1.9	7
35	Management of anticoagulant-refractory thrombotic antiphospholipid syndrome. Lancet Haematology, the, 2020, 7, e613-e623.	4.6	6
36	Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment. Current Rheumatology Reports, 2017, 19, 50.	4.7	5

#	ARTICLE	IF	CITATIONS
37	Use of direct oral anticoagulants in antiphospholipid syndrome: Reply. Journal of Thrombosis and Haemostasis, 2020, 18, 259-261.	3.8	5
38	Coexistent antiphospholipid syndrome and myeloproliferative neoplasm. Lupus, 2021, 30, 1502-1508.	1.6	4
39	Comparing pregnancy outcomes in patients with criteria and non-criteria autoimmune disease: A systematic review. Lupus, 2022, 31, 5-18.	1.6	4
40	Pathogenesis of Antiphospholipid Antibody Syndrome. , 2019, , 324-337.		3
41	Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis. , 2017, , 77-116.		3
42	The Natural History of Uterine Venous Plexus Thrombosis. Diagnostics, 2021, 11, 1338.	2.6	2
43	Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository. Advances in Rheumatology, 2021, 61, 64.	1.7	0